Analyses in a middle-european cohort of elderly reveal a high prevalence of anemia and indicate a relevant proportion of so far undiagnosed myelodysplastic syndromes

or 2nd line) collected from regional database in Limousin network 3C (Coordination Center of Cancer) including pts of CHU Limoges or HEMATOLIM. All cases have been discussed by a pluridisciplinary team for therapeutic decision: 1-Intensive Chemotherapy (ICT), 2HMA (VIDAZA) with courses 75 mg/m/day x 5-7 days every 4 weeks with Home care (Hospital at home: HAH) or 3-Best Supportive Care (BSC). Results: 2003-2013, 538 AML pts fulfilled all inclusion criteria. Sexratio:1,15, median age:71 y-o (15-99), pts N65 y-o: 67%(360/538). Treatments are known for 97% pts (521/538): respectively ICT : 46%(n = 240), HMA : 15%(n = 78), BSC : 39% (n = 203), distributed for N65 y-old pts : 22%(77/346) / 21.5%(94/346) / 56.5%(195/346), and distributed by age group: 65-70: 61%/19.5%/19.5%; 70-75: 38%/ 22%/40%; 75-80: 6.5%/27%/66.5%; N80: 0%/17%/83%, and by years: 2003-2006 :30%/1%/69%;2007-2010: 20%/23.5%/ 56.5%; 2011-2012: 22%/41%/37%. HMA pts n = 138 (1st intention or 2nd to treat (n = 76, 55%), post treatment relapse 1 or 2 (n = 41, 30%). A significant increase in access to HMA in AML pts was observed from 1% in 2003-2006, to 41% in 2011-2012. HAH: 41% (56/138) with no significant difference 2 years OS with ICT but a significant OS advantage in comparison to BSC.